At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 12 enrolled
Drug / intervention
Ambrisentandrug
Likely dose
Ambrisentan 5mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Exercise Induced Pulmonary Hypertension in Systemic Sclerosis and Treatment With Ambrisentan: A Prospective Single Center, Open Label, Pilot Study
In Brief
A Phase 4 clinical trial evaluating Ambrisentan for Systemic Sclerosis and 2 related conditions. Completed, enrolled 12 participants across 1 site.
Detailed Summary
The purpose of this study is to determine the clinical characteristics and hemodynamic profiles that predict exercise induced pulmonary hypertension in 15 patients with systemic sclerosis. The study also aims to determine the effectiveness of Ambrisentan for subjects with exercise induced Pulmonary Arterial Hypertension (PAH) with scleroderma
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
CollaboratorsGilead Sciences
Timeline
Phase 4CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartMar 2009
First PostedJan 2010
Primary CompletionJun 2010
Study CompletionJan 2011
TodayJul 2026
First PostedJan 20, 2010
Enrollment StartMar 1, 2009
Primary CompletionJun 1, 2010
Study CompletionJan 1, 2011
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 16.4 years ago
Interventions
Ambrisentandrug
Ambrisentan 5mg or 10mg once daily